title: [Effects of acetylsalvianolic acid A on arachidonic acid metabolism in platelets].
abstract: Acetylsalvianolic acid A (ASAA) has been shown to be an antiplatelet compound. Our studies with RIA showed that: at the dosage of inhibiting platelet aggregation, ASAA was found to inhibit the formation of cyclooxygenase pathway metabolites TXB2 in platelets. In addition, ASAA was also shown to promote the formation of 6-keto-PGF1 alpha in rabbit aortic rings in vitro. The above results suggest that ASAA may inhibit the proaggregator TXA2 formation, promote mildly the antiaggregator PGI2 generation and probably, whereby, exert its antiplatelet activity.
authors.affiliation: Institute of Materia Medica, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100050.
authors.forename: W
authors.initials: W
authors.lastname: Yu
authors.forename: L
authors.initials: L
authors.lastname: Xu
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000818:Animals; D001011:Aorta / Q000378:metabolism; D016718:Arachidonic Acid / Q000378:metabolism*; D001792:Blood Platelets / Q000378:metabolism*; D002109:Caffeic Acids / Q000494:pharmacology*; D007773:Lactates / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011817:Rabbits; D013929:Thromboxane B2 / Q000097:blood
chemical_list: D002109:Caffeic Acids; D007773:Lactates; D010975:Platelet Aggregation Inhibitors; C090844:acetylsalvianolic acid A; D016718:Arachidonic Acid; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha